BR112018002342A2 - polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos - Google Patents

polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos

Info

Publication number
BR112018002342A2
BR112018002342A2 BR112018002342A BR112018002342A BR112018002342A2 BR 112018002342 A2 BR112018002342 A2 BR 112018002342A2 BR 112018002342 A BR112018002342 A BR 112018002342A BR 112018002342 A BR112018002342 A BR 112018002342A BR 112018002342 A2 BR112018002342 A2 BR 112018002342A2
Authority
BR
Brazil
Prior art keywords
delivery
methods
genetically modified
intrinsically disordered
stealth polymers
Prior art date
Application number
BR112018002342A
Other languages
English (en)
Inventor
Chilkoti Ashutosh
Bhattacharyya Jayanta
YOUSEFPOUR Parisa
Banskota Samagya
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of BR112018002342A2 publication Critical patent/BR112018002342A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

trata-se de conjugados que incluem um polipeptídeo e uma ou mais molé-culas de fármaco. o polipeptídeo inclui um ou mais motivos carregados e pode in-cluir, adicionalmente, um ou mais motivos não carregados. os conjugados podem ser usados para entregar, de maneira eficaz, a molécula de fármaco a um indivíduo.
BR112018002342A 2015-08-04 2016-08-04 polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos BR112018002342A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562200726P 2015-08-04 2015-08-04
PCT/US2016/045655 WO2017024182A1 (en) 2015-08-04 2016-08-04 Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same

Publications (1)

Publication Number Publication Date
BR112018002342A2 true BR112018002342A2 (pt) 2018-12-11

Family

ID=57943998

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018002342A BR112018002342A2 (pt) 2015-08-04 2016-08-04 polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos

Country Status (12)

Country Link
US (1) US11458205B2 (pt)
EP (1) EP3331557B1 (pt)
JP (1) JP6882782B2 (pt)
KR (1) KR20180033586A (pt)
CN (1) CN108463244B (pt)
AU (1) AU2016301391B2 (pt)
BR (1) BR112018002342A2 (pt)
CA (1) CA2994279A1 (pt)
EA (1) EA037478B1 (pt)
MX (1) MX2018001511A (pt)
WO (1) WO2017024182A1 (pt)
ZA (1) ZA201800939B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2016154530A1 (en) 2015-03-26 2016-09-29 Duke University Targeted therapeutic agents comprising multivalent protein-biopolymer fusions
AU2016301391B2 (en) 2015-08-04 2022-07-28 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
CN109890833A (zh) 2016-09-14 2019-06-14 杜克大学 用于递送亲水性药物的基于三嵌段多肽的纳米粒子
JP2020500150A (ja) 2016-09-23 2020-01-09 デューク ユニバーシティ 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
WO2020028806A1 (en) 2018-08-02 2020-02-06 Duke University Dual agonist fusion proteins
CN113195514A (zh) * 2018-10-10 2021-07-30 华盛顿大学 包含混合电荷肽的融合产物和生物缀合物
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
WO2021252391A1 (en) * 2020-06-09 2021-12-16 Academia Sinica Methods and vectors for enhancing expression and/or inhibiting degradation of protein

Family Cites Families (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4976734A (en) 1985-10-31 1990-12-11 Uab Research Foundation Stimulation of chemotaxis by chemotactic peptides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5336256A (en) 1986-04-17 1994-08-09 Uab Research Foundation Elastomeric polypeptides as vascular prosthetic materials
US5250516A (en) 1986-04-17 1993-10-05 Uab Research Foundation Bioelastomeric materials suitable for the protection of burn areas or the protection of wound repair sites from the occurrence of adhesions
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5362623A (en) 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
JP2763958B2 (ja) 1990-06-11 1998-06-11 ネクスター ファーマスーティカルズ，インコーポレイテッド 核酸リガンド
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
EP0668766A1 (en) 1992-10-23 1995-08-30 University Of Massachusetts Medical Center Small molecule inhibition of rna/ligand binding
US5534408A (en) 1993-09-24 1996-07-09 University Of Massachusetts Medical Center 2-deoxystreptamine aminoglycoside inhibition of HIV RRE/Rev binding
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6541580B1 (en) 1995-03-31 2003-04-01 Carnegie Mellon University Atom or group transfer radical polymerization
US5763548A (en) 1995-03-31 1998-06-09 Carnegie-Mellon University (Co)polymers and a novel polymerization process based on atom (or group) transfer radical polymerization
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
CA2279986A1 (en) 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6974669B2 (en) 2000-03-28 2005-12-13 Nanosphere, Inc. Bio-barcodes based on oligonucleotide-modified nanoparticles
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6841617B2 (en) 2000-09-28 2005-01-11 Battelle Memorial Institute Thermogelling biodegradable aqueous polymer solution
US7087244B2 (en) 2000-09-28 2006-08-08 Battelle Memorial Institute Thermogelling oligopeptide polymers
US6296831B1 (en) 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
AU752942B2 (en) 1998-04-13 2002-10-03 Massachusetts Institute Of Technology Comb copolymers for regulating cell-surface interactions
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
CA2337129A1 (en) 1998-07-13 2000-01-20 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US6413587B1 (en) 1999-03-02 2002-07-02 International Business Machines Corporation Method for forming polymer brush pattern on a substrate surface
WO2000056774A1 (en) 1999-03-19 2000-09-28 Duke University Methods of using bioelastomers
US7163712B2 (en) 2000-03-03 2007-01-16 Duke University Microstamping activated polymer surfaces
US20050255554A1 (en) 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US6852834B2 (en) 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US7351376B1 (en) 2000-06-05 2008-04-01 California Institute Of Technology Integrated active flux microfluidic devices and methods
US6660247B1 (en) 2000-06-23 2003-12-09 Battelle Memorial Institute Multiple stimulus reversible hydrogels
US6649138B2 (en) 2000-10-13 2003-11-18 Quantum Dot Corporation Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
EP1911461B1 (en) 2000-10-19 2011-12-07 Epimmune Inc. HLA class I and II binding peptides and their uses
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US6528287B2 (en) 2001-02-13 2003-03-04 Nestor D. Tomycz Recombinant human serum transferrins containing peptides for inducing apoptosis in HIV-1 infected cells
EP1384022A4 (en) 2001-04-06 2004-08-04 California Inst Of Techn AMPLIFICATION OF NUCLEIC ACID USING MICROFLUIDIC DEVICES
WO2002081372A2 (en) 2001-04-06 2002-10-17 Carnegie Mellon University A process for the preparation of nanostructured materials
IL159053A0 (en) 2001-05-25 2004-05-12 Univ Duke Modulators of pharmacological agents
EP1423514A2 (en) 2001-09-05 2004-06-02 WHATMAN plc Stable storage of proteins
WO2003045309A2 (en) 2001-11-21 2003-06-05 The Trustees Of The University Of Pennsylvania Peptides, peptide compositions,and methods of use in binding p 185
JP4355210B2 (ja) 2001-11-30 2009-10-28 フルイディグム コーポレイション 微小流体デバイスおよび微小流体デバイスの使用方法
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US20040101852A1 (en) 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of CGG triplet repeat binding protein 1 expression
BR0309877A (pt) 2002-05-03 2005-04-26 Millenium Biologix Inc Peptìdeos estimuladores de tecido conectivo
EP1558444B1 (en) 2002-06-24 2016-09-21 Tufts University Silk biomaterials and methods of use thereof
PT1534340E (pt) 2002-09-06 2012-03-13 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US6918284B2 (en) 2003-03-24 2005-07-19 The United States Of America As Represented By The Secretary Of The Navy Interconnected networks of single-walled carbon nanotubes
WO2004096124A2 (en) 2003-04-01 2004-11-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2005034843A2 (en) 2003-09-17 2005-04-21 Macropore Biosurgery Inc. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US7335744B2 (en) 2003-12-23 2008-02-26 The Regents Of The California University Prostate cancer specific internalizing human antibodies
EP2460811A1 (en) 2004-04-22 2012-06-06 Regado Biosciences, Inc. Improved modulators of coagulation factors
WO2006004778A2 (en) 2004-06-30 2006-01-12 Dentsply International Inc. Implant with a biofunctionalized surface and method for its production
US7884185B2 (en) 2004-07-28 2011-02-08 University Of Delaware Hydrogels and uses thereof
CA2583700A1 (en) 2004-08-11 2006-02-23 Arqule, Inc. Quinone prodrug compositions and methods of use
WO2006110292A2 (en) 2005-03-25 2006-10-19 The Regents Of The University Of California Temperature-triggered immobilization and purification of antibodies
CN101535499B (zh) 2005-05-09 2017-04-19 赛拉诺斯股份有限公司 点护理流体系统及其应用
KR101446503B1 (ko) 2005-06-24 2014-10-06 듀크 유니버시티 열 반응성 생중합체에 기초한 직접 약물 전달 시스템
EP1924654B1 (en) 2005-08-25 2020-05-06 University of Washington Super-low fouling sulfobetaine and carboxybetaine materials and related methods
WO2007035527A2 (en) 2005-09-15 2007-03-29 Duke University Non-fouling polymeric surface modification and signal amplification method for biomolecular detection
CA2634034A1 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US7709227B2 (en) 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
US8841414B1 (en) 2006-01-27 2014-09-23 University Of Mississippi Medical Center Targeted delivery of therapeutic peptides by thermally responsive biopolymers
EP1996236A2 (en) 2006-03-22 2008-12-03 National Institute of Immunology Novel bioconjugates as therapeutic agent and synthesis thereof
WO2007134245A2 (en) 2006-05-12 2007-11-22 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
SI2409988T1 (sl) 2006-06-13 2015-10-30 Helix Biomedix Inc. Peptidni fragmenti za sprožitev sinteze proteinov zunajcelične matrice
CN101505872B (zh) 2006-06-23 2011-12-28 意法半导体股份有限公司 用于分析生物材料的微流控装置的组件
AU2007265628B2 (en) 2006-06-23 2012-12-06 Perkinelmer Health Sciences, Inc. Methods and devices for microfluidic point-of-care immunoassays
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
US20110039776A1 (en) 2006-09-06 2011-02-17 Ashutosh Chilkoti Fusion peptide therapeutic compositions
US8846624B2 (en) 2006-09-11 2014-09-30 Emory University Modified protein polymers
WO2008043041A1 (en) 2006-10-04 2008-04-10 University Of Washington Method and device for rapid parallel microfluidic molecular affinity assays
WO2008055931A1 (de) 2006-11-08 2008-05-15 Basf Se Verwendung von natürlichen, rekombinanten und synthetischen resilinen in der kosmetik
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
CA2682580A1 (en) 2007-03-30 2008-10-09 Duke University A method of modulating the activity of a nucleic acid molecule
DK2190863T3 (en) 2007-07-31 2015-11-30 Affibody Ab New albumin binding compositions, methods and uses
US8366652B2 (en) 2007-08-17 2013-02-05 The Invention Science Fund I, Llc Systems, devices, and methods including infection-fighting and monitoring shunts
US20090098652A1 (en) 2007-08-17 2009-04-16 Northwestern University Self assembling peptide systems and methods
ES2319061B1 (es) 2007-09-11 2010-02-10 Biomedal, S.L. Metodo de conservacion de peptidos o proteinas.
EP3756767B1 (en) 2007-10-02 2024-05-01 Labrador Diagnostics LLC Modular point-of-care devices and uses thereof
US20110207673A1 (en) 2007-11-20 2011-08-25 Ashutosh Chilkoti Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
DE102007057802B3 (de) * 2007-11-30 2009-06-10 Geneart Ag Steganographische Einbettung von Informationen in kodierenden Genen
BRPI0820738A2 (pt) 2007-12-14 2015-06-16 Minitube America Inc Separação específica do gênero de células de esperma e embriões
US8796184B2 (en) 2008-03-28 2014-08-05 Sentilus, Inc. Detection assay devices and methods of making and using the same
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
KR101026468B1 (ko) 2008-09-10 2011-04-01 한국전자통신연구원 생분자 검출 장치 및 검출 방법
US20110230420A1 (en) 2008-11-17 2011-09-22 Enzon Pharmaceuticals, Inc. Releasable conjugates for nucleic acids delivery systems
WO2010054699A1 (en) 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
MX2011005967A (es) 2008-12-05 2011-06-30 Abraxis Bioscience Llc Peptidos enlazados a sparc y usos de los mismos.
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
US8497356B2 (en) 2009-02-17 2013-07-30 Duke University Biomolecule polymer conjugates and methods for making the same
EP2440235A1 (en) 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
USPP21973P3 (en) 2009-06-23 2011-06-14 Cellfor Inc. Loblolly pine tree named ‘CF LP1-7696’
EP2287221A1 (en) 2009-07-16 2011-02-23 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Method for the preparation of high molecular weight oligo(alkylene glycol) functionalized polyisocyanopeptides
EP2470200B1 (en) * 2009-08-26 2017-03-15 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2011035465A1 (zh) 2009-09-22 2011-03-31 上海市肿瘤研究所 特异性结合蛋白及其使用
US8602051B2 (en) 2009-12-10 2013-12-10 Brent W. Proper Trap-primer system for floor drains
US8961977B2 (en) 2010-02-12 2015-02-24 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
WO2011119484A1 (en) * 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2011123813A2 (en) * 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
JP2011220803A (ja) 2010-04-08 2011-11-04 Mitsumi Electric Co Ltd 電界効果トランジスタ素子を具備するバイオセンサ
EP2560684A4 (en) 2010-04-13 2013-11-20 Medimmune Llc FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
EP3305192B1 (en) 2010-05-17 2019-10-09 Sentilus Holdco, LLC Detection devices and related methods of use
EP2418284A1 (en) 2010-08-13 2012-02-15 ERA Biotech, S.A. Protein body-inducing polypeptide sequences
WO2011155565A1 (ja) 2010-06-10 2011-12-15 国立大学法人九州工業大学 可逆的な性質を示す温度応答性シートとそれを用いた細胞シートの製造方法
EP2616797B1 (en) 2010-09-15 2017-01-11 MBIO Diagnostics Inc. System and method for detecting multiple molecules in one assay
US8470967B2 (en) 2010-09-24 2013-06-25 Duke University Phase transition biopolymers and methods of use
JP6189215B2 (ja) 2010-11-01 2017-08-30 ペプチメッド， インコーポレイテッド 細胞特異的ターゲティングのためのペプチドに基づいたシステムの組成物
WO2012162426A1 (en) 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heptameric targeting ligands
KR101357117B1 (ko) 2011-06-28 2014-02-06 비앤엘델리팜 주식회사 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
US9775803B2 (en) 2011-10-19 2017-10-03 Samsung Electronics Co., Ltd. Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof
WO2013059805A1 (en) 2011-10-21 2013-04-25 Decimadx, Llc Point-of care immunoassay for quantitative small analyte detection
WO2013065009A1 (en) 2011-11-01 2013-05-10 National Institute Of Immunology A sortase-click reaction suite for synthesis of multivalent dendrimeric protein assembly
WO2013082116A1 (en) 2011-11-28 2013-06-06 Phasebio Pharmaceuticals, Inc. Therapeutic agents comprising insulin amino acid sequences
EP2802308A1 (en) 2012-01-13 2014-11-19 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130197359A1 (en) 2012-02-01 2013-08-01 Samsung Electronics Co., Ltd. Solid lipid nanoparticles including elastin-like polypeptides and use thereof
BR112015004734A2 (pt) 2012-09-07 2017-11-21 Sanofi Sa proteínas de fusão para tratar uma síndrome metabólica
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
JP2014156428A (ja) 2013-02-15 2014-08-28 Univ Of Tokyo 抗体結合タンパク質
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR102109188B1 (ko) 2013-04-01 2020-05-11 삼성전자주식회사 양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2014194244A1 (en) 2013-05-30 2014-12-04 Duke University Enzyme-catalyzed synthesis of site-specific and stoichiometric biomolecule-polymer conjugates
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
WO2015011231A1 (en) 2013-07-25 2015-01-29 Universitat Rovira I Virgili Method and system for the multiplex identification of analytes in fluids
US9777041B2 (en) 2013-09-09 2017-10-03 New York University Protein nanofibers from self-assembling pentamers
WO2015051199A2 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
RU2672055C2 (ru) 2013-11-01 2018-11-09 Йейл Юниверсити Модульные частицы для иммунотерапии
WO2015126480A2 (en) 2013-11-13 2015-08-27 Massachusetts Institute Of Technology Self-assembling underwater adhesives
US11268127B2 (en) 2014-02-04 2022-03-08 Duke University Systems and devices for protease detection based on engineered polymers and biopolymers and methods of use
US10501734B2 (en) 2014-02-06 2019-12-10 Yale University Compositions and methods of use thereof for making polypeptides with many instances of nonstandard amino acids
WO2015130846A2 (en) 2014-02-25 2015-09-03 Duke University Compositions and methods for the site-specific modification of polypeptides
US10131690B2 (en) 2014-04-25 2018-11-20 Phi Pharma Sa C6S specific transporter molecules
BR102014014502B1 (pt) 2014-06-13 2020-09-15 Ouro Fino Saúde Animal Ltda Vetor de expressão
CN104877127B (zh) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
CN104725628B (zh) 2014-10-01 2018-04-17 厦门赛诺邦格生物科技股份有限公司 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
WO2016065300A1 (en) 2014-10-24 2016-04-28 Eshoo Mark W Microfluidic cartridge
WO2016065273A1 (en) 2014-10-24 2016-04-28 The University Of Chicago Heat-inducible self-assembling protein domains
EP3227348A4 (en) 2014-12-04 2018-07-18 The Trustees of Columbia University in the City of New York Biodegradable thermo-responsive polymers and uses thereof
US9702847B2 (en) 2014-12-30 2017-07-11 Avails Medical, Inc. Systems and methods for detecting a substance in bodily fluid
US9804170B2 (en) 2015-02-09 2017-10-31 Bristol-Myers Squibb Company Antibodies to polyethylene glycol
US9956300B2 (en) 2015-03-18 2018-05-01 Duke Univerity Hydrogels formed from polypeptide micelles and methods of use thereof
WO2016154530A1 (en) 2015-03-26 2016-09-29 Duke University Targeted therapeutic agents comprising multivalent protein-biopolymer fusions
US10064954B2 (en) 2015-06-23 2018-09-04 Nian Wu Polymer-cyclodextrin-lipid conjugates
AU2016287499B2 (en) 2015-06-29 2022-08-04 Caris Science, Inc. Therapeutic oligonucleotides
ES2865259T3 (es) 2015-07-20 2021-10-15 Sentilus Holdco LLC Chips, detectores y métodos para fabricarlos y utilizarlos
AU2016301391B2 (en) 2015-08-04 2022-07-28 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
EP3332254A1 (en) 2015-08-07 2018-06-13 POC Medical Systems Inc. Microfluidic devices and methods of use thereof
US9678037B2 (en) 2015-10-08 2017-06-13 The Regents Of The University Of Michigan Two-dimensional material-based field-effect transistor sensors
CA3040110A1 (en) 2015-10-13 2017-04-20 Daniel C. Carter Nsp10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
JP7030690B2 (ja) 2015-10-28 2022-03-07 アキィタス・セラピューティクス・インコーポレイテッド 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤
WO2017083423A1 (en) 2015-11-10 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating aav infection
US9496239B1 (en) 2015-12-11 2016-11-15 International Business Machines Corporation Nitride-enriched oxide-to-oxide 3D wafer bonding
US20190015520A1 (en) 2015-12-21 2019-01-17 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
CN108884458A (zh) 2016-03-31 2018-11-23 味之素株式会社 丝心蛋白样蛋白质改造体及细胞培养方法
AU2017261216B2 (en) 2016-05-06 2023-08-03 Immunoforge Co., Ltd. ELP fusion proteins for controlled and sustained release
CN110352071A (zh) 2016-10-26 2019-10-18 库瑞瓦格股份公司 脂质纳米颗粒mRNA疫苗
CN110087671A (zh) 2016-12-22 2019-08-02 赛诺菲 具有优化的活性比率的fgf21化合物/glp-1r激动剂组合
US11684584B2 (en) 2016-12-30 2023-06-27 Genevant Sciences Gmbh Branched peg molecules and related compositions and methods
AU2018214601A1 (en) 2017-02-02 2019-08-15 Caris Science, Inc. Targeted oligonucleotides
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
GB2608903B (en) 2017-06-14 2023-04-05 Emulate Inc Effects of space travel on human brain cells
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
US11235324B2 (en) 2017-11-22 2022-02-01 Hewlett-Packard Development Company, L.P. Temperature-cycling microfluidic devices
US20210060171A1 (en) 2018-01-26 2021-03-04 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
US20190292549A1 (en) 2018-03-22 2019-09-26 Northeastern University Poly(ethylene glycol) brushes for efficient rna delivery
CN112867475B (zh) 2018-08-17 2024-03-22 加利福尼亚大学董事会 具有单分散流体体积的含颗粒液滴系统
US20220146502A1 (en) 2019-02-01 2022-05-12 Sentilus Holdco, Llc High-sensitivity assay

Also Published As

Publication number Publication date
EP3331557A1 (en) 2018-06-13
AU2016301391B2 (en) 2022-07-28
CN108463244B (zh) 2022-05-27
JP6882782B2 (ja) 2021-06-02
KR20180033586A (ko) 2018-04-03
CN108463244A (zh) 2018-08-28
EP3331557A4 (en) 2019-03-13
US11458205B2 (en) 2022-10-04
AU2016301391A1 (en) 2018-02-22
CA2994279A1 (en) 2017-02-09
JP2018525989A (ja) 2018-09-13
EA201890417A1 (ru) 2018-08-31
MX2018001511A (es) 2018-08-01
WO2017024182A1 (en) 2017-02-09
ZA201800939B (en) 2019-05-29
EP3331557B1 (en) 2021-04-07
US20180228908A1 (en) 2018-08-16
EA037478B1 (ru) 2021-04-01

Similar Documents

Publication Publication Date Title
BR112018002342A2 (pt) polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
BR112018010018A2 (pt) moduladores de ror-gama
NI201800038S (es) Dispositivo de administración de medicamento intranasal
BR112017007543A2 (pt) peptídeos com propriedades anti-inflamatórias
BR112017016503A2 (pt) conjugado de fármaco de citotoxicidade-ligante, método de preparação para o mesmo, e aplicação para o mesmo
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
EA033345B1 (ru) ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ
CY1123720T1 (el) Συνθεσεις ενος πολυορθοεστερα και ενος εκδοχου οργανικου οξεος
BR112018077541A2 (pt) formulações orais gastrorretentivas e usos das mesmas
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
CL2016000148A1 (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
BR112017008867A2 (pt) inibidores de proteína quinases
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
BR112019006075A2 (pt) medicamento
BR112017020404A2 (pt) medicamento
BR112017016388A2 (pt) cenicriviroc para o tratamento da fibrose
BR112017001888A2 (pt) formulações biológicas para instilação intravesical
DK3453390T3 (da) Farmaceutisk sammensætning indeholdende polymeriseret lægemiddel
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
BR112017004552A2 (pt) composições farmacêuticas
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]